KYMR Q3 2020 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+1429.8% YoY

Gross Profit

$15M100.0% margin

Operating Income

-$8M-55.6% margin

Net Income

-$8M-55.0% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+342.0%

Cash Flow

Operating Cash Flow

$132M

Free Cash Flow

$129M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$507M

Total Liabilities

$213M

Stockholders' Equity

$295M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$950,000	+1429.8%
Gross Profit	$15M	$950,000	+1429.8%
Operating Income	-$8M	-$12M	+31.9%
Net Income	-$8M	-$11M	+30.1%